Mesenchymal stem cells: immune evasive, not immune privileged.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and clinical literature without new human empirical data
PubMed 24561556 · doi:10.1038/nbt.2816
What was done
This narrative review examined the immunological properties of allogeneic mesenchymal stem/stromal cells (MSCs), evaluating evidence regarding whether MSCs are genuinely immune privileged or merely immune evasive, and analyzing the clinical implications for allogeneic cell therapies.
What was found
The abstract reports no quantitative data. It highlights that recent literature demonstrates donor-directed antibody generation and immune rejection following allogeneic MSC transplantation. However, it notes that whether immune rejection alters therapeutic efficacy is currently unknown, and autologous MSCs have not demonstrated a clear clinical advantage over allogeneic preparations.
Why it matters
This paper reframes the paradigm of allogeneic MSC therapy by demonstrating that off-the-shelf donor cells are subject to immune detection and rejection, which may cause patient allo-sensitization.
Limits
The abstract contains no original experimental data, quantitative metrics, or systematic study search criteria. Whether prolonging MSC survival in vivo actually improves clinical outcomes remains unproven.
Cited by
- contradicts Placental stem cells have not been thymized and do not provoke an immune reaction when administered to any recipient.